Response Genetics to Net $2.2M in Placement of Common Stock | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Response Genetics today said that it will sell 1,175,512 shares of its common stock to certain institutional investors, raising net proceeds of around $2.2 million.

The Los Angeles-based molecular diagnostics firm said that it would sell the shares at a price of $1.99 each through a registered direct offering to certain, unnamed investors. It expects to close the offering tomorrow.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Harold Varmus, a former NIH director, says that proposed reductions to the agency's budget are worrisome.

The Genome 10K project is to sequence about 10,000 vertebrate genomes, including ones of endangered species, Digital Trends reports.

The new Coalition to Save NIH Funding aims to educate lawmakers and the public on the significance of biomedical research.

In PLOS this week: analysis of viral sequences from human blood samples, gut microbiomes of heart failure patients, and more.